| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/02/2010 | US7671091 Administering vasodilator in carrier or diluent |
| 03/02/2010 | US7671090 Inhibitors of α4 mediated cell adhesion |
| 03/02/2010 | US7671089 Levodopa prodrugs, and compositions and uses thereof |
| 03/02/2010 | US7671088 Water-soluble etoposide analogs and methods of use thereof |
| 03/02/2010 | US7671087 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| 03/02/2010 | US7671086 Pharmaceutical compositions comprising flavonoids and menthol |
| 03/02/2010 | US7671085 Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
| 03/02/2010 | US7671084 Dibenzo chromene derivatives and their use as ERβ selective ligands |
| 03/02/2010 | US7671083 organic field-effect transistors; high mobility and high on/off ratio; 5,5'-di(4-octyloxy-phenyl)-2,2'-bithiophene |
| 03/02/2010 | US7671082 4-Amino-2,2-dioxo-2 lambda 6-thia-bicyclo[3.1.0]hexane-4,6-dicarboxylic acid diethyl ester; glutamate receptor agonist; antidepressant, anxiolytic agent psychological, and psychiatric disorders; acylation amino compounds with amino acyl, deprotection |
| 03/02/2010 | US7671081 Multifunctional cationic photoinitiators, their preparation and use |
| 03/02/2010 | US7671080 5-chloro-1-(2,5-dimethylbenzyl)-1H-indole-2-carboxylic acid (3-hydroxy-2,2-dimethylpropyl)amide; nicotine dependence, obesity |
| 03/02/2010 | US7671079 Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands |
| 03/02/2010 | US7671078 1,3-dicyclohexyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea; 1,3-dicycloheptyl-2-(6,6-dimethyl-5,6-dihydroimidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea; CXC chemokine Receptor |
| 03/02/2010 | US7671077 Kits for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis (ALS) |
| 03/02/2010 | US7671076 N-(4-piperidin-1-yl-phenyl)-2-[5-(thiaxolidine-3-carbonyl)-pyrrolidin-3-ylidene]-acetamide;antidiabetic agents; hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis |
| 03/02/2010 | US7671075 Therapy and prophylaxis of Alzheimer's Disease and Down's syndrome; inhibiting beta amyloid production; 2,4-difluoro-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]benzenesulfonamide |
| 03/02/2010 | US7671074 Have an affinity for the gabapentin binding site and can be used to treat conditions such as pain, epilepsy, migraine and others; N-{amino-[pyridin-2-yl-methyl)-amino]-methylene}-4-methylbenzenesulfonamide |
| 03/02/2010 | US7671073 4-{(1S,2S)-2-Amino-3-[(3S)-3-fluoropyrrolidin-1-yl]-1-methyl-3-oxopropyl}-1-[1,2,4]triazolo[1,5-a]pyridin-6-ylcyclohexanol, bis(trifluoroacetic acid); non-insulin dependent (Type 2) diabetes, hyperglycemia; dipeptidyl peptidase-IV inhibitors |
| 03/02/2010 | US7671072 benzyl-carbamic acid cis-3-[5-(cyclohexanecarbonyl-amino)-1H-pyrazol-3-yl]-cyclobutyl ester; glycogen synthase kinase-3 (GSK-3) inhibitors; inter alia, Alzheimer's Disease, cancer, dementia, depression, diabetes, hair loss, schizophrenia, and stroke |
| 03/02/2010 | US7671071 Crystal structure; antihistamines; histamine H1-antagonists; side effect reduction; storage stability |
| 03/02/2010 | US7671070 For therapy of ophthalmic, otic and nasal infections, particularly bacterial infections; conjunctivitis treatment with moxifloxacin hydrochloride |
| 03/02/2010 | US7671069 chemokine receptor modulators; tumor cell proliferation, metastasis, inflammatory diseases, HIV, stem cell differentiation and mobilization disorders, and ocular disorders; N-[2-(cyclohexylmethylamino)-ethyl]-2-(8-Methyl-4-oxo-4H-chromeno[4,3-C]pyrazol-1-yl)-acetamide |
| 03/02/2010 | US7671068 N-(alkoxyalkyl) carbamoyl-substituted 6-phenyl-benzonaphthyridine derivatives and their use as PDE ¾ inhibitors |
| 03/02/2010 | US7671067 Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
| 03/02/2010 | US7671066 Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors |
| 03/02/2010 | US7671065 Pyridine derivatives as potassium ion channel openers |
| 03/02/2010 | US7671064 angiogenesis inhibitors; as antitumor agents; kinase inhibitors like vascular endothelial growth factor receptors antagonists |
| 03/02/2010 | US7671063 2,4 Di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or syk inhibitors |
| 03/02/2010 | US7671062 N-((1R,2S,5R)-5-(isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide; antiinflammatory agent, anticarcinogenic agent; for treating allergic, autoimmune, metabolic, cancer, cardiovascular diseases |
| 03/02/2010 | US7671061 Methods and compositions for treating pain |
| 03/02/2010 | US7671060 5-[3-[(2S)-1-(difluoromethoxy)propan-2-yl]oxy-5-[(5-methylpyrazin-2-yl)carbamoyl]phenoxy]-N,N-dimethyl-pyrazine-2-carboxamide; for diseases mediated through glucokinase (GLK) such as type 2 diabetes |
| 03/02/2010 | US7671059 (S)-2-Amino-6-benzyl-7-[4-fluoro-2-(2-fluoro-pyridin-3-yl)-phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one;cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases |
| 03/02/2010 | US7671058 N-(3,4-disubstituted phenyl) salicylamide derivatives |
| 03/02/2010 | US7671057 Therapeutic agent for type II diabetes comprising protease-inhibiting compound |
| 03/02/2010 | US7671056 5-fluoro-8-(4-(4-(6-methoxyquinolin-8-yl)piperazin-1-yl)piperidin-1-yl)quinoline; central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction |
| 03/02/2010 | US7671055 Insecticidal 3-(dihaloalkenyl) phenyl derivatives |
| 03/02/2010 | US7671054 Reverse-turn mimetics and method relating thereto |
| 03/02/2010 | US7671053 such as 2-chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide for treatment of asthma and COPD; purinergic receptors (P2X7) |
| 03/02/2010 | US7671052 Phenyl derivatives and methods of use |
| 03/02/2010 | US7671051 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 |
| 03/02/2010 | US7671050 (4-Methoxyphenyl)-[3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine; phosphodiesterase inhibitors |
| 03/02/2010 | US7671049 1-{3-[(6-amino-5-nitropyridin-2-yl)amino]propyl}-4-(2,4-dichlorophenyl)-N-[(1S)-2-hydroxy-1-methylethyl]-1H-pyrrole-3-carboxamide; Antidiabetic, hypotensive, antiischemic, anticarcinogenic agents; Alzheimer*s disease, obesity, polycystic ovary syndrome; brain, neurodegenerative and autoimmune diseases |
| 03/02/2010 | US7671048 gamma-aminobutyric acid GABA receptors inverse agonists ; Alzheimer's disease, cognition enhancers; cyclopropyl-[3-fluoro-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepin-10-yl]-methanone, |
| 03/02/2010 | US7671047 Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
| 03/02/2010 | US7671046 Target Atp binding sites; ruthenium and platinum are fused to nitrogen heterocyclic ligands; stability and selectivity; anticancer agents |
| 03/02/2010 | US7671045 carcinoma and adenocarcinomas of the breast; Type II diabetes mellitus; 19,24-Dinorchola-4,9,20-trien-3-one, 17,23-epoxy-11-[4-(5,5-Dimethyl-2-oxo-2 lambda 5-[1,3,2]dioxaphosphinan-2-yl)-phenyl]-, (11 beta ,17 alpha )-(9Cl) |
| 03/02/2010 | US7671044 Pharmaceutical formula for treating skin disease |
| 03/02/2010 | US7671043 3-{4-[5-(4-isobutyl-phenyl)-[1,2,4]oxadiazole-3-yl]-benzylamino}-cis-cyclobutanecarboxylic acid; for treatment of hyperproliferative diseases and autoimmune diseases in mammals; modulators of the sphingosine-1-phosphate (S1P) receptors |
| 03/02/2010 | US7671042 Pharmaceutical compositions containing cyclodextrins and taxoids |
| 03/02/2010 | US7671041 Glycosaminoglycans; food complements, medicaments; joint pain, obesity; bioavailability |
| 03/02/2010 | US7671040 Concurrent administering cancer drug and glucan; synergistic mixture |
| 03/02/2010 | US7671039 Composition containing beta-glucan for prevention and treatment of osteoporosis |
| 03/02/2010 | US7671038 suppressing cachexia-wasting, improving skeletal muscle functions and/or slowing cancer progression by administering adenosine 5'-monophosphate, adenosine 5'-diphosphate, adenosine 5'-triphosphate; liposomes |
| 03/02/2010 | US7671037 Hypoxia induced mitogenic factor |
| 03/02/2010 | US7671036 Positively-charged peptide nucleic acid analogs with improved properties |
| 03/02/2010 | US7671035 Epidermal growth factor receptor antisense oligonucleotides |
| 03/02/2010 | US7671034 Controlling the amount of an already existing antioxidant or stabilizer; decrease or to prevent the formation of acid/base catalyzed decomposition of the active ingredient |
| 03/02/2010 | US7671031 delivering an amphetamine by administering to said subject in need L-lysine-d-amphetamine or a salt thereof; providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity |
| 03/02/2010 | US7671030 Administering L-lysine-d-amphetamine or salts |
| 03/02/2010 | US7671027 use of agonist of hypothalamic hormone, i.e. GnRH, for preparation to support luteal phase during infertility treatment of female mammals; pharmaceutical agent supports luteal phase after spontaneous ovulation or after stimulation of follicular growth triggering final follicular maturation and ovulation |
| 03/02/2010 | US7671019 Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) |
| 03/02/2010 | US7671017 Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV) |
| 03/02/2010 | US7670990 N-{2-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]ethyl }-2-trifluoromethylbenzamide; can be combined with other fungicides which provide mixtures showing a synergistic effect |
| 03/02/2010 | US7670799 dissolving the TCPP in an aqueous alcoholic solution; efficient solubilizing, improved staining ; for detect dysplastic, pre-cancerous, and cancerous cells from various tissue samples both in vitro and in situ |
| 03/02/2010 | US7670791 regulating an alpha 1G T-type calcium channel in the central nervous system and alpha 1H and alpha 1I T-type calcium channels in the peripheral nervous system; analegesic |
| 03/02/2010 | US7670632 Saponin mixtures and compounds isolated from Acacia victoriae; glycosides of acacic or oleanolic acid; control of cell apoptosis and cytotoxicity; antitumor, -carcinogenic, -inflammatory and -proliferative agents; atherosclerosis |
| 03/02/2010 | US7670630 Composition for treating cancer cells and preparation method for the same |
| 03/02/2010 | US7670626 Encapsulated bioactive bisphosphonate such as alendronate including mono- or diglyceride of caproic or capric acid enhancer or surfactant comprising ethylene oxide-propylene oxide block copolymer |
| 03/02/2010 | US7670625 Pharmaceutical composition containing an active ingredient and a micronised carrier/diluent |
| 03/02/2010 | US7670621 A device for delivering fesoterodine (fumarate) through the skin in a dosage ofo.r-20 mg per day and is provided in a polymer matrix for uniform release;contact adhesives; sel-adhesives; impermeable backing; flatness; geratrics;drug delivery; side effect reduction |
| 03/02/2010 | US7670620 Topical composition for the treatment of psoriasis and related skin disorders |
| 03/02/2010 | US7670619 A bilayer tablet for the treating of nervous system disorders associated with serotonin deficiencies having a rapid-release layer of 5-hydroxytryptophan and a slow-release layer of tryptophan or 5-hydroxytryptophan; physiological conditions; side effect reduction |
| 03/02/2010 | US7670617 Sequential drug delivery systems |
| 03/02/2010 | US7670614 emulsifier based on sugars having excellent dispersion without it being necessary to add dispersants; antiagglomerants |
| 03/02/2010 | US7670606 Method for administering a vaginal care composition |
| 03/02/2010 | US7670601 Using uterine tumor specific marker as diagnostic tool in detection of urogenital specific cell proliferative disorders |
| 03/02/2010 | US7670599 Using monoclonal antibody as diagnostic and therapeutic tool in treatment and prevention of cell proliferative and degenerative bone disorders; immunotherapy |
| 03/02/2010 | US7670591 Heteroaryl substituted benzoxazoles |
| 03/02/2010 | US7670590 Perturbed membrane-binding compounds and methods of using the same |
| 03/02/2010 | US7670491 Buffered compositions for dialysis |
| 03/02/2010 | CA2665501A1 Methods and compositions for the treatment and prevention of bone loss |
| 03/02/2010 | CA2519117C High potency dopaminergic treatment of neurological impairment associated with brain injury |
| 03/02/2010 | CA2394615C Substituted 1,3,4-oxadiazoles and a method of reducing tnf-.alpha. levels |
| 03/02/2010 | CA2373833C Medicinal compositions for preventing or treating viral myocarditis |
| 03/02/2010 | CA2292836C Prostaglandin pharmaceutical compositions |
| 03/01/2010 | CA2640879A1 Liquid formulation containing a taxane derivative |
| 02/25/2010 | WO2010022381A1 Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
| 02/25/2010 | WO2010022380A2 Linear polyol stabilized polyfluoroacrylate compositions |
| 02/25/2010 | WO2010022358A1 6-substituted 2-(benzimidazolyl)purine and purinone derivatives and 6-substituted 2-(imidazoio[4,5- c]pyridinyl)purine and purinone derivatives for immunosuppression |
| 02/25/2010 | WO2010022355A1 Compounds and methods for treating respiratory diseases |
| 02/25/2010 | WO2010022313A2 Processes for the preparation of sglt2 inhibitors |
| 02/25/2010 | WO2010022307A2 Prolyl hydroxylase inhibitors |
| 02/25/2010 | WO2010022304A1 Methods for treating cns disorders |
| 02/25/2010 | WO2010022300A1 Methods for treating neuropathic pain |
| 02/25/2010 | WO2010022279A1 Antibodies and related molecules that bind to 58p1d12 proteins |
| 02/25/2010 | WO2010022277A2 Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers |
| 02/25/2010 | WO2010022259A1 Short acting benzothiazepine calcium channel blockers and uses thereof |
| 02/25/2010 | WO2010022249A2 Macrocyclic compounds for inhibition of tumor necrosis factor alpha |
| 02/25/2010 | WO2010022243A1 Chemoprevention of head and neck squamous cell carcinomas |